020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years

Conclusions After 6 years of follow-up, rates of patients with CDP24 and risk of requiring a walking aid remained lower in earlier initiators of ocrelizumab (OCR-OCR) versus those initially receiving IFN (IFN-OCR), demonstrating maintained benefits of earlier treatment with ocrelizumab. g.giovannoni@qmul.ac.uk
Source: Journal of Neurology, Neurosurgery and Psychiatry - Category: Neurosurgery Authors: Tags: Poster Presentations Source Type: research